Exelixis pained by FDA SPA no-show but pushes ahead with cabozantinib
This article was originally published in Scrip
Executive Summary
Despite failing to secure a special protocol assessment with the US FDA, Exelixis has decided to proceed with the '306 trial, its first Phase III pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer (CRPC).